In Silico Study of Different Thrombolytic Agents for Fibrinolysis in Acute Ischemic Stroke
Open Access
- 28 February 2023
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (3) , 797
Abstract
Alteplase is the only FDA-approved drug for thrombolysis in acute ischemic stroke (AIS). Meanwhile, several thrombolytic drugs are deemed to be promising candidates to substitute alteplase. This paper evaluates the efficacy and safety of urokinase, ateplase, tenecteplase, and reteplase for intravenous AIS therapy by computational simulations of the pharmacokinetics and pharmacodynamics combined with a local fibrinolysis model. The performances of the drugs are evaluated by comparing clot lysis time, plasminogen activator inhibitor (PAI) inhibition resistance, intracranial hemorrhage (ICH) risk, and activation time from drug administration to clot lysis. Our results reveal that urokinase has the quickest lysis completion but the highest ICH risk due to excess fibrinogen depletion in systemic plasma. While tenecteplase and alteplase have very similar thrombolysis efficacy, tenecteplase has a lower risk of ICH and better resistance to PAI-1. Among the four simulated drugs, reteplase has the slowest fibrinolysis rate, but fibrinogen concentration in systemic plasma is unaffected during thrombolysis.Keywords
This publication has 44 references indexed in Scilit:
- Outcome Evaluation of Intravenous Infusion of Urokinase for Acute Ischemic StrokeChonnam Medical Journal, 2012
- Medical Therapy for Ischemic Stroke: Review of Intravenous and Intra-Arterial Treatment OptionsWorld Neurosurgery, 2011
- Review of tenecteplase (TNKase) in the treatment of acute myocardial infarctionVascular Health and Risk Management, 2009
- Pharmacokinetics and Pharmacodynamics of Tenecteplase in Fibrinolytic Therapy of Acute Myocardial InfarctionClinical Pharmacokinetics, 2002
- Pharmacokinetics and Pharmacodynamics of Tenecteplase: Results from a Phase II Study in Patients with Acute Myocardial InfarctionThe Journal of Clinical Pharmacology, 2000
- Identification of the Mechanism Responsible for the Increased Fibrin Specificity of TNK-Tissue Plasminogen Activator Relative to Tissue Plasminogen ActivatorJournal of Biological Chemistry, 2000
- Current Clinical Use of Reteplase for ThrombolysisClinical Pharmacokinetics, 1999
- Thrombolytic Therapy with Streptokinase in Acute Ischemic StrokeNew England Journal of Medicine, 1996
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- A pilot study of urokinase therapy in cerebral infarction.Stroke, 1976